Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

91.23 +0.98 (+1.09%)
Streaming Delayed Price Updated: 2:11 PM EDT, Sep 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 406,089
Open 91.07
Bid (Size) 91.13 (100)
Ask (Size) 91.33 (100)
Prev. Close 90.25
Today's Range 89.65 - 94.06
52wk Range 14.51 - 110.17
Shares Outstanding 101,192,921
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
From Spyre Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+198.3%
+198.3%
1 Month
-14.3%
-14.3%
3 Month
-9.1%
-9.1%
6 Month
+113.4%
+113.4%
1 Year
+496.7%
+496.7%

More News

Read More
Wednesday's pre-market session: top gainers and losers ↗
Via Chartmill
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
Via The Motley Fool
News headline image
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Via The Motley Fool

Frequently Asked Questions

Is Spyre Therapeutics, Inc. - Common Stock publicly traded?
Yes, Spyre Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Spyre Therapeutics, Inc. - Common Stock trade on?
Spyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Spyre Therapeutics, Inc. - Common Stock?
The ticker symbol for Spyre Therapeutics, Inc. - Common Stock is SYRE on the Nasdaq Stock Market
What is the current price of Spyre Therapeutics, Inc. - Common Stock?
The current price of Spyre Therapeutics, Inc. - Common Stock is 91.23
When was Spyre Therapeutics, Inc. - Common Stock last traded?
The last trade of Spyre Therapeutics, Inc. - Common Stock was at 09/21/26 02:11 PM ET
What is the market capitalization of Spyre Therapeutics, Inc. - Common Stock?
The market capitalization of Spyre Therapeutics, Inc. - Common Stock is 9.23B
How many shares of Spyre Therapeutics, Inc. - Common Stock are outstanding?
Spyre Therapeutics, Inc. - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.